Erratum: Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (The Lancet (2017) 390(10106) (1949–1961) (S0140673617324406) (10.1016/S0140-6736(17)32440-6));Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet

Volumn 390, Issue 10106, 2017, Pages 1949-1961

  Coleman, Robert L ^a   Oza, Amit M ^b   Lorusso, Domenica ^c   Aghajanian, Carol ^d   Oaknin, Ana ^e   Dean, Andrew ^f   Colombo, Nicoletta ^g   Weberpals, Johanne I ^h   Clamp, Andrew ⁱ   Scambia, Giovanni ^j   Leary, Alexandra ^k   Holloway, Robert W ^l   Gancedo, Margarita Amenedo ^m   Fong, Peter C ⁿ   Goh, Jeffrey C ^o   O'Malley, David M ^p   Armstrong, Deborah K ^q   Garcia Donas, Jesus ^r   Swisher, Elizabeth M ^s   Floquet, Anne ^t   Konecny, Gottfried E ^u   McNeish, Iain A ^v   Scott, Clare L ^w   Cameron, Terri ^x   Maloney, Lara ^x   Isaacson, Jeff ^x   Goble, Sandra ^x   Grace, Caroline ^x   Harding, Thomas C ^x   Raponi, Mitch ^x   Sun, James ^y   Lin, Kevin K ^x   Giordano, Heidi ^x   Ledermann, Jonathan A ^z   Buck, M ^aa   Dean, A ^aa   Friedlander, M L ^aa   Harnett, P ^aa   Kichenadasse, G ^aa   Denys, H ^aa   Dirix, L ^aa   Vergote, I ^aa   Elit, L ^aa   Ghatage, P ^aa   Plante, M ^aa   Provencher, D ^aa   Welch, S ^aa   Gladieff, L ^aa   Joly, F ^aa   Lortholary, A ^aa   Lotz, J ^aa   Medioni, J ^aa   Tredan, O ^aa   You, B ^aa   El Balat, A ^aa   Hanle C ^aa   Krabisch, P ^aa   Neunhoffer T ^aa   Polcher M ^aa   Wimberger, P ^aa   Amit, A ^aa   Kovel, S ^aa   Leviov, M ^aa   Safra, T ^aa   Shapira Frommer, R ^aa   Stemmer, S ^aa   Bologna, A ^aa   Pignata, S ^aa   Sabbatini, R F ^aa   Tamberi, S ^aa   Zamagni, C ^aa   O'Donnell, A ^aa   Herraez, A Casado ^aa   Guerra, E M ^aa   Palacio, I ^aa   Romero, I ^aa   Sanchez, A ^aa   Banerjee, S N ^aa   Drew, Y ^aa   Gabra, H G ^aa   Jackson, D ^aa   Ledermann, J A ^aa   Parkinson, C ^aa   Powell, M ^aa   Birrer, M J ^aa   Buss, M K ^aa   Chambers, S K ^aa   Chen, L M ^aa   Ma, L ^aa   Morgan, M A ^aa   Morris, R T ^aa   Mutch, D G ^aa   Slomovitz, B M ^aa   Vanderkwaak, T ^aa   Vulfovich, M ^aa   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^f St John of God Subiaco Hospital   (Australia)

^g EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^h OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

^j CATHOLIC UNIVERSITY   (Italy)

^k INSERM   (France)

^l FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^m Regional Cancer Center of Galicia   (Spain)

ⁿ AUCKLAND CITY HOSPITAL   (New Zealand)

^o ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^p OHIO STATE UNIVERSITY   (United States)

^q JOHNS HOPKINS UNIVERSITY   (United States)

^r Facultad HM Hospitales de Ciencias de la Salud de la UCJC   (Spain)

^s UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^t INSTITUT BERGONIÉ   (France)

^u UNIVERSITY OF CALIFORNIA   (United States)

^v UNIVERSITY OF GLASGOW   (United Kingdom)

^w ROYAL MELBOURNE HOSPITAL   (Australia)

^x Clovis Oncology Inc   (United States)

^y FOUNDATION MEDICINE   (United States)

^z UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^aa NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC METAL COMPLEX; ASPARTATE AMINOTRANSFERASE; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; HEMOGLOBIN; PLACEBO; RUCAPARIB; INDOLE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE MYELOID LEUKEMIA; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER RECURRENCE; CARCINOMATOUS PERITONITIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; ENDOMETRIOID CARCINOMA; FATIGUE; FEMALE; FEVER; GENE MUTATION; GERMLINE MUTATION; HEART ARREST; HEMOGLOBIN DETERMINATION; HETEROZYGOSITY LOSS; HOMOLOGOUS RECOMBINATION; HUMAN; INTESTINE OBSTRUCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEXT GENERATION SEQUENCING; OUTCOME ASSESSMENT; OVARY CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECOMBINATION REPAIR; SIDE EFFECT; SOMATIC MUTATION; TREATMENT DURATION; TREATMENT INTERRUPTION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UTERINE TUBE CARCINOMA; VOMITING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG THERAPY; FOLLOW UP; INTERNATIONAL COOPERATION; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; OVARY TUMOR; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; INTERNATIONALITY; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85029218556     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)32702-2     Document Type: Erratum

References (30)

1. International Agency for Reasearch on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/summary_table_pop_sel.aspx (accessed Aug 1, 2017).
2. McMeekin, DS, Tillmanns, T, Chaudry, T, et al. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer. Gynecol Oncol 95 (2004), 157–164.
3. Herzog, TJ, Holloway, RW, Stuart, GC, Workshop: options for therapy in ovarian cancer. Gynecol Oncol 90 (2003), S45–S50.
4. Aghajanian, C, Blank, SV, Goff, BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30 (2012), 2039–2045.
5. Ledermann, J, Harter, P, Gourley, C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366 (2012), 1382–1392.
6. Mirza, MR, Monk, BJ, Herrstedt, J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375 (2016), 2154–2164.
7. Coleman, RL, Brady, MF, Herzog, TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18 (2017), 779–791.
8. Ledermann, JA, Embleton, AC, Raja, F, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 387 (2016), 1066–1074.
9. Pujade-Lauraine, E, Ledermann, JA, Selle, F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18 (2017), 1274–1284.
10. Kristeleit, R, Shapiro, GI, Burris, HA, et al. A phase I–II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res 23 (2017), 4095–4106.
11. Swisher, EM, Lin, KK, Oza, AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 18 (2017), 75–87.
12. Watkins, JA, Irshad, S, Grigoriadis, A, Tutt, AN, Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res, 16, 2014, 211.
13. Abkevich, V, Timms, KM, Hennessy, BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107 (2012), 1776–1782.
14. Pedersen, B, Konstantinopoulos, PA, Spillman, MA, De, S, Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients. Genes Chromosomes Cancer 52 (2013), 794–801.
15. Marquard, AM, Eklund, AC, Joshi, T, et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res, 3, 2015, 9.
16. Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
17. Rustin, GJ, Vergote, I, Eisenhauer, E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21 (2011), 419–423.
18. Jensen, SE, Rosenbloom, SK, Beaumont, JL, et al. A new index of priority symptoms in advanced ovarian cancer. Gynecol Oncol 120 (2011), 214–219.
19. Brown, EG, Wood, L, Wood, S, The Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf 20 (1999), 109–117.
20. Rahma, OE, Duffy, A, Liewehr, DJ, Steinberg, SM, Greten, TF, Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol 24 (2013), 1972–1979.
21. Westfall, PH, Krishen, A, Optimally weighted, fixed sequence and gatekeeper multiple testing procedures. J Stat Plan Inf 99 (2001), 25–40.
22. Temple, R, Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 15 (2006), 241–243.
23. U.S. Department of Health and Human Services. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/Guidances/UCM174090.pdf, July, 2009 (accessed Aug 22, 2017).
24. Lynparza (olaparib) capsules (prescribing information), 2017, AstraZeneca, Wilmington http://www.azpicentral.com/pi.html?product=lynparza_tb&country=us&popup=no (accessed Sept 7, 2017).
25. Rubraca (rucaparib) tablets (prescribing information), 2017, Clovis Oncology, Boulder http://clovisoncology.com/files/rubraca-prescribing-info.pdf (accessed Sep 7, 2017).
26. McCormick, A, Swaisland, H, In vitro assessment of the roles of drug transporters in the disposition and drug–drug interaction potential of olaparib. Xenobiotica 47 (2017), 903–915.
27. Kikuchi, R, Lao, Y, Bow, DA, et al. Prediction of clinical drug–drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K). J Pharm Sci 102 (2013), 4426–4432.
28. Konecny GE, Oza AM, Tinker AV, et al. Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Annual Meeting on Women's Cancer 2017; National Harbor, USA; March 12–15, 2017. abstract 1.
29. Oaknin A, Oza A, Tinker AV, et al. Integrated efficacy and safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC). ECCO2017: European Cancer Congress; Amsterdam, Netherlands; Jan 27–30, 2017. Abstract 710.
30. Ledermann, J, Harter, P, Gourley, C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15 (2014), 852–861.